LEADER 02065nam  2200553   450 
001 9910808292403321
005 20230803024305.0
010   $a1-78084-228-7
035   $a(CKB)2560000000152108
035   $a(EBL)1179640
035   $a(SSID)ssj0001599924
035   $a(PQKBManifestationID)16306517
035   $a(PQKBTitleCode)TC0001599924
035   $a(PQKBWorkID)14892692
035   $a(PQKB)10870922
035   $a(MiAaPQ)EBC1179640
035   $a(Au-PeEL)EBL1179640
035   $a(OCoLC)877767288
035   $a(EXLCZ)992560000000152108
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCurrent & emerging therapeutics for multiple myeloma /$feditors, Noopur Raje, Sundar Jagannath
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (141 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-230-9 
327   $aTitle page; Copyright page; Contents; Foreword. Current and emerging therapeutics for multiple myeloma; 1. Current standard treatment of myeloma; 2. Stem cell transplantation; 3. New immune modulators; 4. Histone deacetylase inhibitors; 5. Targeted treatment of multiple myeloma: proteasome inhibitors; 6. AKT inhibitors in multiple myeloma; 7. Future directions; Index
330   $aCurrent & Emerging Therapeutics for Multiple Myeloma
517 3 $aCurrent and emerging therapeutics for multiple myeloma
606   $aMultiple myeloma$xTreatment
606   $aMultiple myeloma$xChemotherapy
615  0$aMultiple myeloma$xTreatment.
615  0$aMultiple myeloma$xChemotherapy.
676   $a616.99418
702   $aRaje$b Noopur
702   $aJagannath$b Sundar
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910808292403321
996   $aCurrent & emerging therapeutics for multiple myeloma$94114267
997   $aUNINA